Monte Rosa Therapeutics Announces The Publication Of Groundbreaking New Discoveries Featured On The Cover Of Science, Titled "Mining The CRBN Target Space Redefines Rules For Molecular Glue-Induced Neosubstrate Recognition"

Author: Benzinga Newsdesk | July 03, 2025 02:16pm

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, "Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition," details how Monte Rosa's proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes. These findings dramatically expand the actionable target space for MGD drug discovery.

Posted In: GLUE